R&D News & Analysis
4 articles
Market Mood
EnergyPathways Appoints Chief Scientific Adviser for Growth
EnergyPathways has appointed a new chief scientific adviser to enhance its research and development efforts. This appointment aims to strengthen the company's strategic initiatives and align its R&D goals with market demands. The addition of the new adviser is part of a broader effort to innovate within the energy sector, although specific financial metrics or forecasts were not disclosed. This strategic move is expected to positively influence EnergyPathways' market position and operational capabilities moving forward.
Read More
Velmenni Research secures funding to enhance AI development
Velmenni Research & Development Pvt Ltd has successfully raised $5 million in funding to further its artificial intelligence projects. This investment signifies potential growth in the AI sector, highlighting increased investor interest in companies focused on innovative technologies. The funding will be utilized to expand their R&D capabilities and accelerate the development of new AI applications. Such advancements may influence market dynamics in the tech sector, particularly for companies engaged in the AI space.
Read More
Legend Biotech (LEGN) Reports $1.9B Sales for CARVYKTI in 2025
Legend Biotech Corporation (LEGN) announced financial results for 2025, achieving $1.9 billion in net trade sales from its CARVYKTI therapy, including ~$555 million in Q4. The company reported a collaboration revenue increase to $277.6 million in the final quarter. With over 10,000 patients treated and a global footprint expanding to 294 sites across 14 markets, LEGN is positioned for growth. Additionally, the company opened a new 31,000-square-foot R&D facility in Philadelphia to support its pipeline advancements.
Read More
Europe's Pharma Sector Facing Decline Amid U.S. Policies and China's Rise
The pharmaceutical industry in Europe is experiencing significant challenges due to President Trump's trade policies and China's rapid advancements in biotech. Since 1990, Europe’s share of global research and development has decreased from nearly 50% to 26%, while the U.S. share increased to 55%. These changes are prompting global pharmaceutical companies to reconsider their investment strategies, particularly as U.S. tariffs on branded drugs may reach up to 100%. As a result, Europe risks falling behind in critical medicine launches and innovation opportunities.
Read More